We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | NASDAQ:GLMD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0096 | -2.48% | 0.3775 | 0.341 | 0.3774 | 0.3985 | 0.3775 | 0.389 | 65,866 | 01:00:00 |
From May 2019 to May 2024
TEL AVIV, Israel, March 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, March 12, 2020, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter and year ended December 31, 2019.
Conference Call & Webcast: | |
Thursday March 12, 2020, 8:30 AM ET | |
Toll Free: | 1-877-425-9470 |
Toll/International: | 1-201-389-0878 |
Israel Toll Free: | 1-809-406-247 |
Conference ID: | 13699345 |
Webcast: | http://public.viavid.com/index.php?id=138184 |
Replay Dial-In Numbers | |
Toll Free: | 1-844-512-2921 |
Toll/International: | 1-412-317-6671 |
Replay Pin Number: | 13699345 |
Replay Start: | Thursday, March 12, 2020, 11:30 AM ET |
Replay Expiry: | Thursday, March 26, 2020, 11:59 PM ET |
About Aramchol and Non-alcoholic Steatohepatitis (NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.
View original content to download multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-financial-results-and-provide-business-update-on-thursday-march-12-301017212.html
SOURCE Galmed Pharmaceuticals Ltd.
Copyright 2020 PR Newswire
1 Year Galmed Pharmaceuticals Chart |
1 Month Galmed Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
